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Abstract
Background: R849 is a neurovirulent g134.5 gene-deficient form of herpes simplex virus type 1 (HSV-1) and has
LacZ genes at the deleted sites of the g134.5 gene. HF is a spontaneously occurring, fusogenic HSV-1 strain. The
purpose of this work was to generate a virus that has the syncytial character of HF, while preserving the g134.5
gene inactivation profile of R849 virus.
Results: Vero cells were infected with R849 and HF simultaneously and two viruses, RH1 and RH2, expressing the
LacZ gene and inducing extensive cell fusion were selected. A polymerase chain reaction (PCR)-based analysis
suggested that one copy of the g134.5 gene is lost in RH1, whereas both copies are lost in RH2, and that the
g134.5 gene is replaced by a R849-derived DNA fragment with the LacZ gene. These viruses produced larger
plaques and more progeny than the parental viruses. Infection with RH2 decreased the viability of oral squamous
cell carcinoma (SCC) cells most strongly. When RH2 was injected into xenografts of oral SCC in nude mice,
multinucleated cells were produced and the growth of the tumors was suppressed significantly.
Conclusion: These results indicate that novel oncolytic HSV-1 vectors can be produced with the genetic
background of the oncolytic HSV-1 HF, and that RH2 is deficient in g134.5 genes and shows extensive cytopathic
effects in oral SCC cells. RH2 may be useful in oncolytic virotherapy for oral SCC.
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Background
Carcinoma of the oral cavity represents 4% of all malig-
nancies in men and 2% in women, with the majority of
these tumors being squamous cell carcinomas (SCCs)
[1]. Despite improvements in both the surgical and
pharmacological management of oral malignancies, the
5-year survival rate for oral cancer is very poor at
approximately 53% mainly because of the advanced state
of the disease at the time of presentation [2]. There is
no effective treatment for advanced symptoms such as
skin metastasis.
Oncolytic virotherapy with herpes simplex virus type 1
(HSV-1) is based on the ability of an attenuated virus to
destroy the infected tumor cells [3-5]. Most cancer
patients have immunity against HSV-1 and require
repeated administration of the HSV-1 vector, so the
virus must be delivered locally to prevent its inactivation
by neutralizing antibodies [6-8]. In this aspect, oral can-
cer has the advantage of accessibility.
A number of HSV-1 vectors have been developed for
solid tumors. Most of these have the main neuroviru-
lence gene g134.5 removed, which severely restricts their
ability to replicate in the adult central nervous system
and cause a latent infection [9,10]. G207 has two dele-
tions at g134.5 and ribonucleotide reductase (UL39)[11].
NV1020 expresses one of the two g134.5 genes allowing
the virus to replicate more efficiently without compro-
mising safety [6,12,13]. OncoVEX
GM-CSF is deleted of
the g134.5 gene, and ICP47, which otherwise blocks anti-
gen presentation. In addition, a granulocyte macrophage
colony-stimulating factor (GM-CSF) gene is inserted to
enhance the immune response to tumor antigens
released after the virus replicates [7]. Another type of
HSV-1 vector developed to improve local antitumor
activity has the ability to form a syncytium [8,14]. HF10,
a clone of HF, is a spontaneously occurring, highly atte-
nuated virus [15-17]. It too can form a large syncytium
in a variety of cell types and has strong anti-tumor
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against breast cancer, pancreatic cancer, and head and
neck cancer [18-20].
We reported that a combination of g134.5 gene-defi-
cient HSV-1 R849 [21] and HF exerted a greater sup-
pressive effect on xenografts of human oral SCC in
nude mice than did repeated injections of R849 [22],
indicating the effectiveness of HF as an oncolytic virus.
We speculated that recombinant forms of these viruses
might be highly fusogenic (as HF) and still lack the neu-
rovirulent g134.5 gene. To examine this possibility, an
attempt was made to select candidate recombinants
after infecting permissive cells with R849 and HF simul-
taneously. An isolate from the cultures, RH2, induced
extensive cell fusion in cell cultures and cancer tissue
and suppressed tumor growth at a low dose.
Materials and methods
Cells and virus
The human oral SCC cell line SAS was obtained from the
Japanese Collection of Research Bioresources (Tokyo,
Japan). SAS cells were cultured in Dulbecco’sm o d i f i e d
Eagle’s medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100
μg/ml streptomycin and grown in an incubator at 37°C in
a humidified atmosphere with 5% CO2. For Vero monkey
kidney cells, Eagle’s minimal essential medium contain-
ing 5% calf serum and 2 mM L-glutamine was used.
HSV-1 mutant R849 [22,23] and HF [15,16] were grown
in semi-confluent Vero cell monolayers. The infectivity
of HSV-1 was determined by plaque formation on Vero
cell monolayers covered with 0.3% methylcellulose.
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
Cells grown in 96-well culture dishes were infected with
HSV-1 at a multiplicity of infection (MOI) of 0.01, while
controls were mock- infected. After incubation for var-
ious intervals, 10 μlo fa5m g / m lM T Ts o l u t i o nw a s
added to each well with 100 μl of medium. Cells were
allowed to incubate for 4 h at 37°C, and then 100 μlo f
0.04 N HCl in isopropanol was added. They were mixed
thoroughly to dissolve the dark blue crystal. After stand-
ing overnight at room temperature, the plates were read
on a Benchmark Plus microplate spectrophotometer
(Bio-Rad Laboratories, Hercules, CA) with a reference
wavelength of 630 nm and a test wavelength of 570 nm.
Background absorbance at 690 nm was subtracted from
the 570 nm reading. Changes from controls (room air)
were calculated.
Polymerase chain reaction (PCR) analysis
The g134.5 and lacZ gene sequences were amplified by
PCR using specific primers [23]: LacZ forward, 5’-
GCGTTACCCAACTTAATCG -3’; and LacZ reverse, 5’-
TGTGAGCGAGTAACAACC -3’ (PCR product; 320
bp), g134.5 forward, 5’-TCGTCGGACGCGGACTCGG-
GAACGGTGGAG-3’ g134.5 reverse, 5’-CTCCACGCC-
CAACTCGGAACCCGCGGTCAG-3’ (PCR product;
132 bp)
The amplification was carried out in a volume of 50 μl
for 30 cycles with a denaturing temperature of 94°C for
30 sec, an annealing temperature of 60°C for 30 sec, and
an extension temperature of 72°C for 2 min using a
GeneAmp PCR system 9700 (Applied Biosystems, CA,
USA). PCR products were subsequently size-fractionated
on 2% agarose gels, stained with 1 μg/ml ethidium bro-
mide and photographed under transmitted UV light.
Digestion of viral DNA and Southern blot analysis
Viral DNA was isolated after the lysis of infected Vero
cells with SDS-proteinase K, repeated phenol-chloro-
form extraction, following the method of Hirt [24], and
ethanol precipitation. For Southern blot analysis, DNA
digested by Bam HI endonuclease (NEW ENGLND Bio-
Labs, MA, USA) was separated by agarose gel electro-
phoresis and transferred to a nylon membrane Hybond-
N+ (Amersham Biosciences, UK). The PCR product of
LacZ was isolated from the gel, subjected to sequencing
and used as a probe. Amplified DNA fragment of LacZ
was labeled by Gene Images AlkPhos Direct Labeling
and Detection System (Amersham Biosciences). After
hybridization, bounded probe was detected with CDP-
Star Detection reagent (Amersham Biosciences).
Animal experiments
Athymic 5-week-old BALB/c (nu/nu) female mice were
obtained from Clea Japan (Tokyo, Japan). Mice were
subcutaneously injected with 1 × 10
6 SAS cells. Once
the tumor reached approximately 5 mm in diameter,
animals were divided into 4 groups of 6 animals each.
Animals were administered a single intratumor (i.t.)
injection of 1 × 10
5 plaque forming units (PFU) of
R849, HF, or RH2 suspended in 50 μl of phosphate-buf-
fered saline (PBS ). Animals in the control group
received PBS instead of HSV-1. The experiment was
started at the time HSV-1 was injected. Bidimensional
tumor measurements were performed for 6 weeks with
calipers, and tumor volume was determined using the
formula for a rotational ellipsoid (L × W
2 × 0.5).
To determine the virus yield in the tumor, an experi-
ment with acute HSV-1 infection was performed.
Tumor-bearing mice received an i.t. injection of 1 × 10
6
PFU of R849, HF, or RH2. The mice were sacrificed at
3, 7, and 14 days after injection of HSV-1 and tumors
were removed. They were suspended in two volumes of
PBS, homogenized and centrifuged after three rounds of
freezing and thawing. The supernatant was harvested
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plaque assay using Vero cell monolayers.
Another series of experiment was performed for
immunohistochemical staining. HSV-1 was injected in
the tumors at a dose of 1 × 10
6 PFUs and the tumors
were removed at 3 and 7 days after injection. Tumors
that received PBS were used for the control. Experi-
ments were performed with the approval of the Institute
of Laboratory Animals, Osaka University Graduate
School of Dentistry.
Histopathological examination and 5-bromo-4-chloro-3-
indolyl-b-D- galactopyranoside (X-gal) staining
For X-gal staining, R849- infected cells were placed in a
fixative containing 0.2% glutaraldehyde and 2% formal-
dehyde in PBS for 1 h, and submerged in cold PBS.
Cells were then left overnight in a substrate solution
containing 1 mg/ml X-gal (Sigma), 5 mM potassium fer-
ricyanide, 5 mM potassium ferrocyanide, and 2 mM
magnesium chloride in PBS and washed with PBS.
Tumors were removed, placed in 10% buffered forma-
lin for fixation, and embedded in paraffin wax. Sections
were stained with hematoxylin and eosin (H-E). For
immunohistochemical staining, endogenous peroxidase
was blocked by incubation in 3% H2O2 in water for 5
min at room temperature. Sections were washed in PBS
and then incubated with rabbit polyclonal antibody
against HSV-1 (diluted 1:500, DAKO, Glostrup, Den-
mark) for 30 min at room temperature. After another
wash, slides were reacted with Envision+System-HRP
Labelled Polymer Anti Rabbit (DAKO) for 30 min at
room temperature. HSV-1 antigen was visualized by
treating with diaminobenzidine (DAB) (DAKO,
Glostrup, Denmark), counterstained with hematoxylin,
and mounted with Entellan (Merck, Darmstadt, Ger-
many). Computer-assisted analysis of immunohisto-
chemical staining was performed using WinROOF
image-processing software (Mitani Corp., Tokyo, Japan).
This software allowed accurate identification and calcu-
lation of the immunostained area [25]. The size (μm
2)
of HSV-1 antigen-positive multinucleated cells was cal-
culated after examining signals in 3 to 5 sections, using
high-power ( × 40 objective and × 10 ocular) magnifica-
tion. At least 3 samples were measured and mean values
± standard deviation (SD) were determined.
Statistical analysis
An SPSS for Windows computer program (SPSS Inc.,
Chicago, IL, USA) was used for statistical analyses.
Results are reported as means ± SD. Comparison of
mean cell viability, plaque size and virus yield in tumors
were achieved using one-way ANOVA, followed by
Tukey’s honestly significant differences (HSD) test. Mean
size of HSV-1 antigen-positive multinucleated cells was
compared using the unpaired t-test. For the repeated
measures part of the analyses of tumor volumes, general
linear model (GLM) procedure was used to conduct a
repeated measures design analyzed. When overall ana-
lyses determined significance, Tukey’s HSD test was used
to examine pairwise differences. P values of less than 0.05
were considered statistically significant.
Results
Production of recombinant viruses in Vero cells
HSV-1 R849 has a LacZ gene inserted at the deleted site
of the g134.5 gene [21]. R849-infected cells became
rounded and showed X-gal staining, indicating the
expression of LacZ. The BamHI profiles of HF10
showed a loss of the B and E fragments and the genome
has a deletion of 3832 bp to the right of the UL and
UL/IRL junction [17]. Cell-fusion appeared in the cells
infected with HF as well as HF10 [22,26]. Schema of the
genomic structure of these viruses are shown in Figure 1.
In this study, an attempt to generate a virus that has the
syncytial character of HF, while preserving the g134.5
gene inactivation profile of R849 virus by recombination
in cell culture was made. For recombination, Vero cells
were infected with R849 and HF simultaneously, at dif-
ferent MOIs. The MOI was 0.01 for R849 and changed
from 0.001 to 0.1 for HF. When the MOI of HF was
0.02 or 0.03, several syncytia with X-gal staining were
observed and syncytia were pick up under a phase con-
trast microscope. Viruses recovered from the syncytia
were diluted and underwent plaque formation in Vero
cells. This cloning procedure was repeated at least five
times and two virus clones showing extensive cell
fusion, RH1 and RH2, were used for further study.
When human oral SCC SAS cells were infected with
R849, and cultured for 24 h, rounded cells were positive
for X-gal staining. Large syncytia were positive for X-gal
staining in RH2-infected cells (Figure 2).
PCR analysis of RH1 and RH2
To determine the presence of the LacZ gene inserted into
the deleted site of the g134.5 gene of R849, the PCR was
performed. A LacZ-specific band of 320 bp was detected in
R849, RH1 and RH2, but not in HF. When DNA extracted
from HSV-1-infected cells was subjected to a Southern blot
analysis using the LacZ gene as a probe, a LacZ-specific
band was detected in R849, RH1 and RH2; the density in
R849 and RH2 was similar, but that in RH1 was reduced
by approximately half (Figure 3). In the PCR analysis for
the g134.5 gene, a specific 132-bp band was detected in HF
a n dR H 1 ,b u tn o ti nR 8 4 9a n dR H 2( F i g u r e3 ) .
Formation of plaques by RH1 and RH2 in SAS cells
The fusogenic ability of HSV-1 strains was examined by
plaque-forming assays in oral SCC cells. SAS infected
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and the cytopathic effect was observed. In the cells
infected with RH1 and RH2, extensive cell fusion was
observed (Figure 4A). Mean plaque size was greater in
RH1 and RH2 than that in HF (RH2 > RH1 > HF); a 2-
fold increase was observed in RH2 as compared with
HF (Figure 4B). There was a significant (P < 0.05) differ-
ence among virus strains.
Production of RH1 and RH2 in SAS cells
The ability of oral SCC cells to support the replication
of HSV-1 strains was examined. SAS cells were infected
with R849, HF, RH1 or RH2 at a MOI of 0.01 and the
virus production was determined at 48, 72, and 96 h
after infection. RH1 and RH2 produced more infectious
virus than the parental viruses. At 96 h after infection,
as compared with the yield of HF, there were 4.2-fold
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Figure 1 Schematic presentation of genomic structures of wild-type HSV-1 strain F, g134.5-deficient HSV-1 R849, and HF10, a clone of
HF that is a spontaneously occurring, highly attenuated HSV-1.
D E
Figure 2 Cytopathic effect of R849 (a) or RH2 (b) in human oral SCC cells. SAS cells were infected with HSV-1 at an MOI of 0.01 and
cultured at 37°C for 24 h. The infected cells were fixed and subjected to X-gal staining.
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Figure 3 PCR and Southern blot analyses for LacZ and g134.5 genes. PCR analysis was performed using primers for LacZ and g134.5 genes
and DNA of HSV-1-infected cells. The PCR products were separated by agarose gel electrophoresis and stained by ethidium bromide. DNA of
HSV-1 infected cells was digested with Bam HI and subjected to Southern blotting using a LacZ-specific probe. Arrows indicate the specific
bands for LacZ and g134.5 genes.
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Figure 4 The plaque size of HSV-1 in oral SCC cells. (A) SAS cells infected with R849, HF, RH1 and RH2 were incubated for 48 h, and the
cytopathic effect was observed. (B) The plaque size was measured. Data are means ± SD of three determinations.
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RH2 (Figure 5).
Suppression of the viability of oral SCC cells by RH and
RH2
The MTT assay measures the activity of mitochondria.
When SAS cells infected with R849, HF, RH1 or RH2 at
an MOI of 0.01 were cultured for 96 h, the values were
decreased to 88, 54, 64 and 38% of the untreated con-
trol, respectively (Figure 6). There was a significant (P <
0.05) difference between HF and RH2.
Histopathology of HSV-1-injected tumors
To examine the expression of HSV-1 antigens, tumors
were injected with R849, HF, or RH2 at a dose of 1 ×
10
6 PFU and subjected to immunohistochemical stain-
ing. Three days after injection, the histological change
caused by R849 was cell rounding and HSV-1 antigens
appeared in these cells. Multinucleated cells appeared
in the tumors that received HF or RH2. Especially,
both HSV-1 antigen-positive and- negative multinu-
cleated giant cells were observed in RH2-injected
tumors (Figure 7). Seven days after the injection of
HSV-1, necrotic parts surrounded by HSV-1 antigen-
positive cells spread in the tumors. Most multinu-
cleated cells became positive for HSV-1 staining in
RH2-injected tumor (Figure 8). When measured at 14
days, the mean size of multinucleated cells induced by
RH2 was significantly greater than that induced by HF
(P < 0.05) (Figure 9).
Viruss yields in oral SCC xenografts in nude mice
To examine the replication of HSV-1 in vivo, SAS xeno-
grafts in nude mice were given 1 × 10
6 PFU of R849,
HF, or RH2 and virus production in the tumors was
examined at 3, 7 and 14 days after injection. The viral
titer declined 7 days after injection, but a slight increase
was observed 14 days in all strains; the titers in R849,
HF and RH2 were 3 × 10
3,2×1 0
4 and 3 × 10
4 PFU/
tumor (g), respectively. There was no significant differ-
ence among the strains (Figure 10). The RH2 harvested
from tumor tissues at 14 days also showed extensive cell
fusion in SAS cells.
Suppressive effect of HSV-1 infection on the growth of
oral SCC xenografts in nude mice
Nude mouse tumors were injected subcutaneously with
R849, HF, or RH2 at a dose of 1 × 10
5 PFU. Control
animals were given PBS. In the control group, tumors
grew rapidly and the tumor volume at 35 days was 3300
mm
3 (Figure 11), whereas the tumor growth of HSV-1-
treated animals was suppressed and the tumor volumes
were less than 2300 mm
3. When tumor volume was
compared at day 35, a significant difference between the
control and HF group or RH2 group (P < 0.05) was
found. No symptoms of neurological abnormality and
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Figure 5 Replication of HSV-1 in human oral SCC cells. SAS cells were infected with R849, HF, RH1 or RH2 at a MOI of 0.01 and virus yield
was determined at various intervals. Data are means of two determinations. Experiments were repeated three times. A representative result is
shown.
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the experiment.
Discussion
Several viruses that kill their target cells through syncy-
tial formation have been described. The HSV-1 vector
Synco-2D has gibbon ape leukemia virus fusogenic
membrane protein (GALV-FMG) to causes syncytia to
spread in the tumor by cell fusion [14]. Israyelyan et al.
[8] reported a syncytial mutation in the gB (Arg to His
change at aa 858) and gK (Ala to Val change at aa 40)
genes to enhance the fusogenicity of OncdSyn. In this
context, a fusogenic HSV-1 under clinical study is
HF10. The genome of HF10 has extensive rearrange-
ments at both ends of the UL region and lacks the
expression of UL56 and LATs[ 2 6 ] .T h el a c ko fU L 5 6
reduces the neuroinvasiveness of HSV without affecting
viral replication in vitro. Diakidi-Kosta et al. [27]
reported that marker transfer experiments and DNA
sequence analysis mapped the syncytial phenotype to a
T-C base substitution at codon 787 of the cytoplasmic
domain of mature gB, that resulted in Leu to Pro substi-
tution and consequently belonged to the syncytial locus.
Indeed, HF10 has an amino acid substitution (Leu to
Pro at aa 787) in glycoprotein B (gB) [26], suggesting
that the syncytial phenotype of HF10 is ascribed to this
amino acid change. HF from which HF10 was cloned
has the characteristics of an oncolytic virus. To con-
struct a novel virus that is less neurovirulent with the
genetic background of HF, Vero cells were infected with
R 8 4 9a n dH Fa td i f f e r e n tM O I s .S i n c eR 8 4 9h a st h e
LacZ gene inserted into the deleted g134.5 gene, the
expression of LacZ is a marker of a R849-specific struc-
ture. We selected fusogenic viruses with the LacZ gene,
and obtained RH1 and RH2. When they were subjected
to PCR and Southern blot analysis, RH1 and RH2
r e v e a l e dt h ep r e s e n c eo ft h eL a c Zg e n e ,b u tt h ed e n s i t y
of the gene was lower in RH1 than in R849 and RH2.
Consistent with this finding, the g134.5 gene was
detected in RH1, but not RH2. Thus, it is concluded
that one copy of the g134.5 gene is lost in RH1, whereas
both copies are lost in RH2, and that the g134.5 gene is
replaced by a R849-derived DNA fragment with the
LacZ gene.
The mean plaque sizes of RH1 and RH2 were signifi-
cantly greater than that of HF, indicating the ability to
induce extensive cell fusion in oral SCC cells. During
the simultaneous infection with R849 and HF, a variety
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Figure 6 Suppressive effect of HSV-1 on the viability of oral SCC cells. SAS cells were infected with R849, HF, RH1, or RH2 at an MOI of 0.01
and cultured at 37°C. Cell viability was measured by the MTT assay. Data are means ± SD of four determinations. Significantly different between
HF and RH2 (P < 0.05).
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Figure 7 Histopathological changes and virus gene expression in oral SCC xenografts in nude mice. Oral SCC xenografts in nude mice
were given 1 × 10
6 PFUs of R849 (a, b), HF (c, d), or RH2 (e, f). Tumors with skin were removed 3 days after infection and subjected to
immunohistochemical staining using antibody against HSV-1. Arrows indicate rounded cells (b) and multinucleated cells (d, f).
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Figure 8 Histopathological changes and virus gene expression in oral SCC xenografts in nude mice. Oral SCC xenografts in nude mice
were given 1 × 10
6 PFUs of R849 (a, b), HF (c, d), or RH2 (e, f). Tumors with skin were removed 7 days after infection and processed as
described in Figure 7. Arrows indicate rounded cells (b) and multinucleated cells (d, f).
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Figure 9 Histopathological changes and virus gene expression in oral SCC xenografts in nude mice. Oral SCC xenografts in nude mice
were given 1 × 10
6 PFUs of HF or RH2. After 3, 5, 7, and 14 days, they were subjected to immunohistochemical staining and the mean size
(μm
2) of HSV-1 antigen-positive multinucleated cells in the sections was determined. Data are means ± SD of three determinations. At 14 days, a
significantly difference was observed between HF and RH2 (*P < 0.05).
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Figure 10 Virus yields in oral SCC xenografts in nude mice. Oral SCC xenografts in nude mice were given 1 × 10
6 PFU of R849, HF, or RH2
and virus production in the tumors was measured 3, 7, and 14 days after infection. Data are means ± SD of three determinations.
Takaoka et al. Virology Journal 2011, 8:294
http://www.virologyj.com/content/8/1/294
Page 9 of 12of recombinants with a unique phenotype with or with-
out the g134.5 gene would be produced, although R849
induces cell rounding. Novel mutations in viral glyco-
protein genes responsible for extensive cell fusion might
occur during or after recombination. It was reported
that OncdSyn with mutations at gB and gK caused
extensive virus-induced cell fusion in cell cultures, but
the titer in tumor cells was a half log lower than that of
the wild-type HSV-1 strain F [8]. Synco-2D with GALV-
FMG has a significantly increased tumor cell killing abil-
ity, but the titer of Synco-2D was also substantially
lower than that of the wild-type HSV strain 17 [14]. In
the present study, we found that the virus production of
RH1 and RH2 was greater than that of the parental
viruses. In the MTT assay, RH2 decreased the cell viabi-
lity most strongly, and RH1 did not exceed the suppres-
sive effect of HF on the growth of tumor cells. Thus,
the virus yield in cell culture is not correlated with the
ability to induce syncytia and cell death. It can be stated
that RH2 has acquired the capability to induce cell
fusion and produce virus progeny in oral SCC cells.
Although a number of fusogenic HSV-1 were investi-
gated for their antitumor effect on tumor tissues, the
histological alteration associated with HSV-1 infection
was not clearly described [8,14,19]. In the present study,
R849 induced cell rounding in tumors as in cell culture
and viral antigen was demonstrated in rounded cells
only. On the other hand, infection with HF or RH2
induced the formation of multinucleated cells. There
was variety in size, but RH2 produced larger multinu-
cleated cells than HF, indicating the phenotype in cell
culture to be preserved in tumor tissues. We also found
multinucleated cells showing only faint staining 3 days
after infection with RH2. The viral antigen may be
diluted in multinucleated cells, because the infection by
RH2 progresses rapidly and involves surrounding unin-
fected cells. The size of HF-induced multinucleated cells
decreased during the observation period, whereas no
such alteration was observed in RH2 (Figure 9). This
represents the difference in the phenotype of these
viruses.
To compare the antitumor ability, we injected R849,
HF or RH2 into nude mouse tumors at a low dose.
Tumors in control animals increased continuously for 5
weeks, while tumor growth was suppressed by the intra-
tumor injection of HSV-1. A significant difference was
demonstrated when HF or RH2 was injected, suggesting
that RH2 has antitumor activity like HF. However, the
antitumor effect of RH2 was slightly blunted. The virus
yields in tumors declined gradually, and a slight increase
was observed in 14 days, irrespective of the virus used.
Thus, these HSV-1s can replicate in the tumors for at
least 14 days. It has been shown that the replication of
g134.5 gene-deficient HSV-1 is dependent on the mito-
gen-activated protein kinase kinase (MEK) activity and/
or phosphoinositide 3-kinase (PI 3-kinase) of the tumor
cells [28-30]. This causes the selective replication of the
HSV-1 vector including RH2 in tumors. In this respect,
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Figure 11 Effect of R849, HF, and RH2 on the growth of oral SCC xenografts in nude mice. Tumor-bearing animals received R849, HF, or
RH2 at a dose of 1 × 10
5 PFU into subcutaneous tumors. Control animals were given PBS. Tumor volume was measured during the experiment.
Data are means ± SD of six determinations. Significantly different between control and HF or RH2 (P < 0.05).
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Page 10 of 12HF still retained the g134.5 gene, so that it can grow in
tissues irrespective of MEK and PI 3-kinase activities in
the tumor cells. This would explain the difference
between HF and RH2 in the antitumor effect and virus
yield. It should be also stated that the phenotype of
RH2, being favorable for oncolytic virotherapy, was sta-
bly maintained after passages in oral SCC cells in cul-
ture and nude mouse tumors. We found neither general
side-effects nor any neurological disorders in the mice,
indicating the low neurovirulence of RH2.
It has been shown that syncytial formation induced by
GALV-FMG of Synco-2D can potentiate antitumor
immune responses through the increased release of vesi-
cles resembling exosomes [14]. Such structures contain
abundant tumor antigens and other molecules involved
in antigen presentation (e.g., MHC class I and class II
molecules) and can efficiently load dendric cells for
cross presentation of tumor antigens [31]. In this regard,
intratumoral inoculation of HF10 into mouse cutaneous
melanoma inhibited the growth of tumors at both
injected and uninjected sites, suggesting the induction of
a systemic antitumor immune response by this fusogenic
HSV-1 [32]. Thus, RH2 may also enhance tumor anti-
gen presentation by syncytial formation. HF10 is under
clinical trials and the genetic structure was published
[18-20,26]. It is apparent that the precise structure of
the RH2 genome must be determined prior to clinical
study.
Conclusion
This work was conducted to generate a virus that has
the syncytial character of HF, while preserving the
g134.5 gene inactivation profile of R849 virus. RH2, a
r e c o m b i n a n tf o r mo fR 8 4 9a n dH F ,h a dad e l e t i o no f
the g134.5 gene and exerted a potent cell killing effect
on oral SCC cells through a highly fusogenic ability.
RH2 may be a candidate for an HF10-based virus vector
suitable for brain tumors as well as oral cancer, because
of its defect in the neurovirulent g134.5 gene.
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